Acetaminophen Dextromethorphan Hydrobromide Pseudo

證據等級: L5

預測適應症: 0 個

ACETAMINOPHEN / DEXTROMETHORPHAN / PSEUDOEPHEDRINE: Combination Cold Remedy — Repurposing Assessment Incomplete

One-Sentence Summary

ACETAMINOPHEN / DEXTROMETHORPHAN HYDROBROMIDE / PSEUDOEPHEDRINE is a classic OTC triple-combination cold remedy targeting pain/fever, cough, and nasal congestion simultaneously. The TxGNN model returned no predicted new indications for this combination entry, most likely because no single DrugBank ID could be resolved for the multi-ingredient query. With 0 clinical trials, 0 publications, and 0 regulatory licenses retrieved, a full repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	Not retrieved (data gap)
Predicted New Indication	None — TxGNN returned no candidates
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and even that is absent)
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction was generated for this query, so a mechanistic rationale for a new indication cannot be constructed from the Evidence Pack.

For context, this fixed-dose combination contains three well-characterized ingredients acting on distinct targets:

Acetaminophen — centrally and peripherally inhibits prostaglandin synthesis; used for analgesia and antipyresis.
Dextromethorphan HBr — NMDA receptor antagonist and sigma-1 receptor agonist acting on the cough center in the medulla; used as an antitussive.
Pseudoephedrine — sympathomimetic amine (α- and β-adrenergic agonist); causes vasoconstriction of nasal mucosa for decongestion.

Because the pipeline could not resolve a single DrugBank ID for this combination string, the knowledge-graph traversal did not produce repurposing candidates. Each individual component (e.g., dextromethorphan alone) has separately documented repurposing literature (e.g., dextromethorphan/quinidine for pseudobulbar affect, NMDA-related neuropathic pain), but those signals are not captured here.

Clinical Trial Evidence

Currently no related clinical trials retrieved for this combination query.

Literature Evidence

Currently no related literature retrieved for this combination query.

Taiwan Market Information

This drug combination holds no Taiwan (TFDA) marketing authorizations. No license table can be generated.

Safety Considerations

All safety fields contain data gaps. Before any further evaluation, the following must be retrieved from official sources:

Key Warnings: Not available — retrieve from TFDA package insert PDF or FDA label (DailyMed)
Contraindications: Not available — pseudoephedrine carries known contraindications (MAOIs, severe hypertension, hyperthyroidism); dextromethorphan interacts with serotonergic agents
Drug Interactions: DDI query returned no results — manual review strongly recommended given pseudoephedrine’s adrenergic profile and dextromethorphan’s serotonin-related risk

Please refer to the individual component package inserts for safety information until a consolidated review is complete.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — no DrugBank ID was resolved, no TxGNN predictions were generated, and all safety fields are flagged as data gaps. There is no basis for a repurposing recommendation at this stage.

To proceed, the following is needed:

Decompose the query: Run TxGNN predictions separately for each active ingredient (acetaminophen DB00316, dextromethorphan DB00514, pseudoephedrine DB00852) and aggregate results
Resolve DrugBank ID: Map the combination string to component IDs to enable knowledge-graph traversal
Retrieve MOA data: Query DrugBank API for each component to support mechanistic analysis
Retrieve safety data: Download TFDA package insert PDF and parse warnings/contraindications (Data Gap DG001)
Re-run Evidence Pack generation: With corrected inputs, re-execute the full pipeline to obtain clinical trial and literature evidence
Confirm Taiwan regulatory status: Verify whether any branded products containing this combination (e.g., compounded products or OTC imports) hold TFDA approval under different trade names
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.